Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?

Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?

Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management

Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management

Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?

On April 20, 2022, Sonja B. Vliek from University Medical Center Utrecht published the results of the TEAM-IIB Phase III clinical trial on the efficacy and safety of oral Ibandronate + endocrine therapy as adjuvant treatment in estrogen receptor-positive, postmenopausal breast cancer patients in the Journal of Clinical Oncology.

The TEAM-IIB Phase III clinical trial was a multicenter, randomized, open-label trial that randomized estrogen receptor-positive, postmenopausal breast cancer patients (N = 1116) in a 1:1 ratio into two groups: Ibandronate (50mg once daily) + endocrine therapy (3-year treatment period) and endocrine therapy alone (5-year treatment period). The primary endpoint was disease-free survival.

At a median follow-up of 8.5 years, the results showed that disease-free survival showed no significant difference between the two groups. The disease-free survival rate at 3 years post-randomization was: Ibandronate + endocrine therapy group 94% versus endocrine therapy group 91%. The 5-year disease-free survival rate was: Ibandronate + endocrine therapy group 89% versus endocrine therapy group 86%.

Regarding safety, 17% (N = 97/565) of patients in the Ibandronate + endocrine therapy group discontinued treatment due to adverse events. The most common adverse effect identified was dyspepsia, occurring in Ibandronate + endocrine therapy group 16% versus endocrine therapy group 10%.

Based on TEAM-IIB results, Sonja B. Vliek and colleagues concluded that estrogen receptor-positive, postmenopausal breast cancer patients receiving oral Ibandronate + endocrine therapy as adjuvant treatment showed no significant improvement in disease-free survival and do not recommend this therapy as standard treatment.

Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.00311

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4